<DOC>
	<DOCNO>NCT01653301</DOCNO>
	<brief_summary>- INTERACT study : evaluate pathological response rate cT3 rectal cancer - LEADER study : evaluate impact local control local excision</brief_summary>
	<brief_title>Preoperative Downstaging Extraperitoneal T3 Rectal Cancer : XELOXRT Versus XELACRT . A Multicenter , Phase III Study</brief_title>
	<detailed_description>- INTERACT study : evaluate pathological response rate evaluate accord TRG scale compare accelerated radiotherapy gross tumour combine plus standard radiotherapy pelvis association chronomodulated capecitabine ( XELACRT arm ) versus oxaliplatin add standard pelvis radiotherapy chronomodulated Capecitabine ( XELOXRT arm ) - LEADER study : evaluate impact local control local excision patient major clinical response evaluate MRI confirm TRG 1-2 score .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>INTERACT STUDY Histologically confirm primary adenocarcinoma rectum . Tumour within 12 cm anal verge proctoscopic examination within 10 cm anorectal ring MRI . Clinical stage ( UICC 1997 ) : cT2N02 low locate tumour , cT3 N02 . Resectable disease routine examination . Age &gt; 18 year . Karnofsky Performance Status &gt; 60 . WBC &gt; 4,000 cells/ml , platelet &gt; 100,000 cells/ml . Provision write informed consent . Evidence metastatic ( M1 ) disease . If suspicious finding ( i.e . liver metastasis , lung nodule , retroperitoneal adenopathy , etc . ) patient consider ineligible , unless malignancy rule tissue documentation ( biopsy ) trial therapy start . Previous chemotherapy , immunotherapy , radiation therapy pelvis . Multiple primary cancer involve colon rectum would preclude patient classified rectal cancer . Incomplete heal surgery . Active inflammatory bowel disease . Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ . Cardiovascular disease New York Heart Association Functional Status &gt; 2 . Absolute neutrophil count ( ANC ) &lt; 4 x 108/L platelet &lt; 50 x 108/L . Measured Creatinine clearance less 65ml/min . ( drug dose reduction lower GFR allow ) . ALT AST &gt; 2.5 time ULRR Pregnancy breastfeeding ( woman childbearing potential ) . Any evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease ) . Any significant clinical disorder laboratory find make undesirable patient participate trial . LEADER STUDY Inclusion Criteria Stage diagnosis : cT3N0 . T3 patient diagnosis 3 less enlarged node , evaluate imaging , without evidence node radiochemotherapy , could accrue accord Center decision , analyze separately . Patients cT2N0 , low locate tumour , otherwise candidate Miles surgical procedure , treat neoadjuvant chemoradiation write consensus ; Major clinical response chemoradiation , yT01N0 ; yT2N0 could accrue accord Center decision , analyze separately . Circumferential extension le 2 quarter ; Deep ulcer &lt; 2 cm diameter ; Provision write informed consent ; Biopsies discourage high risk follow fistula irradiated rectum ; pT3 ; Positive margin ; TRG 35 ; Major adverse feature : lymphatic vessel invasion , vascular vessel invasion , perineural invasion ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>